ANN ARBOR — Leaders from the Michigan biotech industry, academia, and policy realms are joining to discuss how to best drive future business growth at MichBio’s inaugural Michigan Bio-Industry Growth Summit at the Radisson Lansing on Wednesday, Feb. 3.
At the event, the state’s biosciences industry association, MichBio, will release and discuss the Michigan Bio-Industry Strategic Roadmap. The report is the culmination of a year-long strategic planning initiative focusing on how to grow Michigan’s biosciences industry into a market leader. More than 200 stakeholders participated in the grassroots data gathering effort. The initiative is being conducted in partnership with the statewide CIO organziation Business Leaders for Michigan and the University Research Corridor, the association linking the research efforts of Michigan State University, the University of Michigan and Wayne State University.
“Michigan’s bio-industry is at a critical point given the rapidly changing dynamics in the healthcare delivery marketplace, regulatory landscape, and global economy,” said MichBio president and CEO Stephen Rapundalo. “For the state’s bioscience research, development, and manufacturing enterprise to have future success, a shared and executable vision with performance measures is required.”
Scheduled speakers and panelists include Michigan Lt. Gov. Brian Calley; State Sens. Tonya Schuitmaker (R-Lawton) and Rebekah Warren (D-Ann Arbor), State Reps. Sam Singh (D-East Lansing) and Jim Tedder (R-Clarkston); Mark Leahey, CEO of the Medical Device Manufacturers Association; Liz Powell, principal at G2G Consulting of Cleveland; BLM president and CEO Doug Rothwell; Michael J. Jandernoa, director and former CEO of Perrigo Co.; URC executive director Jeff Mason; Stryker Corp. president and CEO Kevin Lobo; Roger Newton, executive chairman and chief scientific officer of Esperion Therapeutics Inc.; and Mina Sooch, CEO of Gemphire Therapeutics.
The Michigan Bio-Industry Roadmap is intended to be an operational game plan to enable growth over the next three to five years. The plan identifies key opportunities with defined actions and metrics. The Roadmap and bio-industry stakeholders focus on functional areas such as: Innovation, industry growth, business climate, capital access and education/talent development. In addition, the Roadmap assessed needs, challenges and opportunities across several bio-industry sectors and market areas where Michigan has a recognized strength and/or potential for growth.
Admission for this event is $99 for MichBio Members and $149 for non-members. Attendees can register at www.michbio.org or by calling (734) 527-9150.